Synthesis and in vitro characterization of ionone-based compounds as dual inhibitors of the androgen receptor and NF-κB

Investigational New Drugs

Volumn 32, Issue 2, 2014, Pages 227-234

  Liu, Weiguo ^a   Zhou, Jinming ^a   Geng, Guoyan ^a   Lin, Rongtuan ^a,b   Wu, Jian Hui ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Androgen receptor; Antiandrogen; IKK ; NF B; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONONE DERIVATIVE; SC 245; SC 97; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HEK293 CELLS; HUMANS; INTERLEUKIN-6; MALE; NF-KAPPA B; NORISOPRENOIDS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84896397503     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0040-y     Document Type: Article

References (36)

1. Taplin ME, Ho SM (2001) The endocrinology of prostate cancer. J Clin Endocrinol Metab 86:3467-3477
2. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
3. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
4. Ang JE, Olmos D, de Bono JS (2009) CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 100:671-675
5. Scher HI, Beer TM, Higano CS et al (2008) Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 26:5006
6. Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790
7. Scher HI, Beer TM, Higano CS et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437-1446
8. Attard G, Cooper CS, de Bono JS (2009) Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16:458-462
9. Taplin ME (2008) Androgen receptor: role and novel therapeutic prospects in prostate cancer. Expert Rev Anticancer Ther 8:1495-1508
10. Yoshida T, Kinoshita H, Segawa T et al (2005) Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 65:9611-9616
11. Steketee K, Timmerman L, Ziel-van der Made AC et al (2002) Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer 100:309-317
12. Taplin ME, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-in dependent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 21:2673-2678
13. Urushibara M, Ishioka J, Hyochi N et al (2007) Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate 67:799-807
14. Joseph JD, Lu N, Qian J et al (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 3:1020-1029
15. Korpal M, Korn JM, Gao X et al (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide). Cancer Discov 3:1030-1043
16. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26
17. Shen HM, Tergaonkar V (2009) NF + B signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14:348-363
18. Setlur SR, Royce TE, Sboner A et al (2007) Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67:10296-10303
19. Gasparian AV, Yao YJ, Kowalczyk D et al (2002) The role of IKK in constitutive activation of NF- + B transcription factor in prostate carcinoma cells. J Cell Sci 115:141-151
20. Lee DF, Hung MC (2008) Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 14:5656-5662
21. Zhang L, Altuwaijri S, Deng F et al (2009) NF- + B regulates androgen receptor expression and prostate cancer growth. Am J Pathol 175:489-499
22. Malinowska K, Neuwirt H, Cavarretta IT et al (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16:155-169
23. Chun JY, Nadiminty N, Dutt S et al (2009) Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 15:4815-4822
24. Feng S, Tang Q, Sun M et al. (2009) Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther
25. Drachenberg DE, Elgamal AA, Rowbotham R et al (1999) Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 41:127-133
26. Jin RJ, Lho Y, Connelly L et al (2008) The nuclear factor- NF-kB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 68:6762-6769
27. Zhou J, Geng G, Shi Q et al (2009) Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. J Med Chem 52:5546-5550
28. Zhou JM, Geng GY, Wu JH (2010) Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Invest New Drugs 28:291-298
29. Zhou J, Geng G, Batist G et al (2009) Syntheses and potential anti-prostate cancer activities of ionone-based chalcones. Bioorg Med Chem Lett 19:1183-1186
30. Attard G, Reid AHM, Olmos D et al (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69:4937-4940
31. Shen HC, Balk SP (2009) Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell 15:461-463
32. Eichholz A, Ferraldeschi R, Attard G et al (2012) Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 360:68-75
33. Krishnan AV, Zhao XY, Swami S et al (2002) A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 143:1889-1900
34. Eder IE, Haag P, Bartsch G et al (2005) Targeting the androgen receptor in hormone-refractory prostate cancer-new concepts. Future Oncol 1:93-101
35. Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39
36. Yemelyanov A, Gasparian A, Lindholm P et al (2006) Effects of IKK inhibitor PS1145 on NF- + B function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25:387-398